Extended Follow-Up Beyond 2.5 Years Demonstrates Long-Term Efficacy in Complete Responders Following Epcoritamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma (R/R LBCL)

被引：0

作者：

Karimi, Yasmin H. ^{[1
]}

Thieblemont, Catherine ^{[2
]}

Ghesquieres, Herve ^{[3
]}

Cheah, Chan Y. ^{[4
,5
]}

Clausen, Michael Roost ^{[6
]}

Cunningham, David ^{[7
]}

Jurczak, Wojciech ^{[8
]}

Linton, Kim M. ^{[9
,10
]}

Hutchings, Martin ^{[11
,12
]}

Phillips, Tycel ^{[13
]}

Farooq, Umar ^{[14
]}

Kim, Won Seog ^{[15
]}

Dinh, Minh H. ^{[16
]}

Ghosh, Jagannath ^{[17
]}

Pallai, Rajash ^{[17
]}

Wielgos-Bonvallet, Monica ^{[17
]}

Eskelund, Christian ^{[18
]}

Lugtenburg, Pieternella J. ^{[19
]}

Vose, Julie M. ^{[20
]}

机构：

[1] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA

[2] Univ Paris, APHP, Hop St Louis, Hematooncol, Paris, France

[3] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Pierre Benite, France

[4] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[5] Univ Western Australia, Nedlands, WA, Australia

[6] Vejle Hosp, Vejle, Denmark

[7] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[8] MSC Natl Res Inst Oncol, Krakow, Poland

[9] Univ Manchester, Christie NHS Fdn Trust, Manchester Canc Res Ctr, Manchester, Lancs, England

[10] Univ Manchester, Div Canc Sci, Manchester, Lancs, England

[11] Rigshosp, Copenhagen, Denmark

[12] Univ Copenhagen, Copenhagen, Denmark

[13] City Hope Natl Med Ctr, Duarte, CA USA

[14] Univ Iowa, Iowa City, IA USA

[15] Samsung Med Ctr, Seoul, South Korea

[16] AbbVie, N Chicago, IL USA

[17] Genmab, Plainsboro, NJ USA

[18] Genmab, Copenhagen, Denmark

[19] Univ Med Ctr, Erasmus MC Canc Inst, Dept Hematol, Rotterdam, Netherlands

[20] Univ Nebraska Med Ctr, Omaha, NE USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷

关键词：

ALL; bispecific; large B-cell lymphoma; hematologic malignancy; non-Hodgkin lymphoma;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ABCL-191

引用

页码：S461 / S462

页数：2

共 50 条

[1] Extended follow-up results beyond 2.5 years from the pivotal NHL-1 EPCORE trial: Subcutaneous epcoritamab monotherapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL)
Karimi, Yasmin
Thieblemont, Catherine
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Jurczak, Wojciech
Linton, Kim M.
Hutchings, Martin
Phillips, Tycel Jovelle
Farooq, Umar
Kim, Won Seog
Dinh, Minh H.
Ghosh, Jagannath
Pallai, Rajash
Wielgos-Bonvallet, Monica
Eskelund, Christian
Lugtenburg, Pieternella
Vose, Julie
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Glofitamab monotherapy in patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study
Dietrich, S.
Falchi, L.
Carlo-Stella, C.
Morschhauser, F.
Hutchings, M.
Bachy, E.
Cartron, G.
Khan, C.
Tani, M.
Martinez-Lopez, J.
Bartlett, N.
Salar, A.
Brody, J.
Leppa, S.
Mulvihill, E.
Lundberg, L.
Relf, J.
Xie, Y.
Bottos, A.
Humphrey, K.
Dickinson, M.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 208 - 208
[3] Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study
Falchi, Lorenzo
Carlo-Stella, Carmelo
Morschhauser, Franck
Hutchings, Martin
Bachy, Emmanuel
Cartron, Guillaume
Khan, Cyrus
Tani, Monica
Martinez-Lopez, Joaquin
Bartlett, Nancy L.
Salar, Antonio
Brody, Joshua
Leppa, Sirpa
Mulvihill, Estafania
Lundberg, Linda
Relf, James
Xie, Yuying
Bottos, Alessia
Humphrey, Kathryn
Dickinson, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Epcoritamab as Standard of Care (SOC) for Relapse/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Dong, Ning
Gaballa, Sameh
Jain, Michael D.
Saeed, Hayder
Kareem, Saba
Corallo, Salvatore
Zhang, Yumeng
Shah, Bijal
Isenalumhe, Leidy
Celeste, Bello
Locke, Frederick
Sokol, Lubomir
Pinilla, Javier
Chavez, Julio
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S456 - S456
[5] Long-term follow-up shows epcoritamab drives deep, durable responses in relapsed/refractory follicular lymphoma (R/R FL)
Izutsu, K.
Akahane, D.
Toubai, T.
Saito, T.
Mishima, Y.
Fujisaki, T.
Kitawaki, T.
Kumode, T.
Suehiro, Y.
Ishitsuka, K.
Conlon, R.
Noguchi, H.
Buchbjerg, J.
Favaro, E.
Fukuhara, N.
ANNALS OF ONCOLOGY, 2024, 35 : S1337 - S1337
[6] Long-Term Follow-Up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Wang, Michael
Rule, Simon
Zinzani, Pier Luigi
Goy, Andre
Casasnovas, Oliver
Smith, Stephen
Damaj, Gandhi
Doorduijn, Jeanette K.
Lamy, Thierry
Morschhauser, Franck
Panizo, Carlos
Shah, Bijal
Davies, Andrew
Eek, Richard
Dupuis, Jehan
Jacobsen, Eric
Kater, Arnon P.
Le Gouill, Steven
Oberic, Lucie
Robak, Tadeusz
Dua, Richa
Frigault, Melanie M.
Izumi, Raquel
Nguyen, Dorothy
Patel, Priti
Yin, Ming
Jurczak, Wojciech
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S316 - S316
[7] Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Wang, Michael
Rule, Simon
Zinzani, Pier Luigi
Goy, Andre
Casasnovas, Olivier
Smith, Stephen D.
Damaj, Gandhi
Doorduijn, Jeanette K.
Lamy, Thierry
Morschhauser, Franck
Panizo, Carlos
Shah, Bijal D.
Davies, Andrew
Eek, Richard
Dupuis, Jehan
Jacobsen, Eric
Kater, Arnon P.
Gouill, Steven L. E.
Oberic, Lucie
Robak, Tadeusz
Dua, Richa
Frigault, Melanie M.
Izumi, Raquel
Nguyen, Dorothy
Patel, Priti
Yin, Ming
Jurczak, Wojciech
BLOOD, 2018, 132
[8] Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up
Rule, Simon
Dreyling, Martin H.
Goy, Andre
Hess, Georg
Auer, Rebecca
Kahl, Brad S.
Angel Hernandez-Rivas, Jose
Qi, Keqin
Deshpande, Sanjay
Parisi, Lori
Wang, Michael L.
BLOOD, 2019, 134
[9] Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Phillips, Tycel
Thieblemont, Catherine
Ghesquieres, Herve
Cheah, Chan Y.
Clausen, Michael Roost
Cunningham, David
Do, Young Rok
Feldman, Tatyana A.
Gasiorowski, Robin
Jurczak, Wojciech
Kim, Tae Min
Lewis, David John
van Der Poel, Marjolein
Poon, Michelle Limei
Kilavuz, Nurgul
Stirner, Mariana Cota
Soong, David
Chiu, Christopher
Chen, Menghui
Sacchi, Mariana
Elliot, Brian
Hutchings, Martin
Lugtenburg, Pieternella
BLOOD, 2022, 140 : 9443 - 9445
[10] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →